Finding the best chemotherapy options for invasive lobular breast cancer patients
Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction tool
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10890145
This study is looking at a specific type of breast cancer called invasive lobular carcinoma to create a helpful tool that can better identify which patients really need chemotherapy, so those who don’t can avoid unnecessary treatment and side effects.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10890145 on ClinicalTrials.gov |
What this research studies
This research focuses on invasive lobular carcinoma (ILC), a type of breast cancer that is often misclassified as low risk despite many patients being clinically high risk. The project aims to develop a clinical prediction tool that helps identify which patients will benefit from chemotherapy, thereby avoiding unnecessary treatment for those who won't. By analyzing unique molecular features of ILC, the research seeks to improve patient selection for chemotherapy and explore personalized treatment options for those predicted to respond poorly. This approach aims to enhance treatment outcomes and minimize side effects for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with invasive lobular carcinoma who are considering chemotherapy as part of their treatment plan.
Not a fit: Patients with other types of breast cancer or those who are not candidates for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized chemotherapy treatments for patients with invasive lobular carcinoma.
How similar studies have performed: While there have been advances in understanding breast cancer treatment, this specific approach to ILC is novel and aims to fill a significant gap in current research.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MUKHTAR, RITA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: MUKHTAR, RITA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer